NCT07345988 Human Babesiosis in Metropolitan France
| NCT ID | NCT07345988 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Human Babesiosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-11-04 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-11-04 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Human babesiosis is a rare zoonosis in Europe caused by protozoa of the genus Babesia, transmitted to humans mainly by ticks of the genus Ixodes. The infection mainly affects individuals who have undergone splenectomy, are immunocompromised, or are elderly, which correspond to the risk factors for the disease. The infection is often underdiagnosed due to its rarity and its often nonspecific clinical presentation (asthenia, fever, flu-like syndrome). In these high-risk patients in particular, the infection can progress to severe forms, with a mortality rate of up to 20-40%. The clinical picture is then that of a severe infection with multiple organ failure: multifactorial renal failure, respiratory distress due to lesion edema, and disseminated intravascular coagulation. One of the main obstacles to understanding human babesiosis in France and Europe is the low number of cases recorded and published. This situation limits knowledge about the epidemiology of the disease, its clinical presentations, its potential severity, and the effectiveness of the treatments used. The aim of this study is to describe the epidemiological, clinical, biological, therapeutic, and prognostic characteristics of human babesiosis cases diagnosed in metropolitan France.
Eligibility Criteria
Inclusion Criteria: * Adult subjects (≥18 years old) * With a diagnosis of babesiosis confirmed by blood smear or PCR * Treated in associated centers during the period from January 1, 2000, to December 31, 2024 Exclusion Criteria: \- Refusal to participate in the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07345988 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Human Babesiosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07345988 currently recruiting?
Yes, NCT07345988 is actively recruiting participants. Contact the research team at victor.gerber@chru-strasbourg.fr for enrollment information.
Where is the NCT07345988 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT07345988 clinical trial?
NCT07345988 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 100 participants.